SABIO-GROUP
8.3.2021 10:02:11 CET | Business Wire | Press release
Sabio Group , a leading European full service CX provider, has acquired makepositive , a large UK-based independent Salesforce consulting partner. makepositive will strengthen Sabio’s ability to support customers with transformative cutting-edge CX technologies, particularly addressing the Human Service aspect of the CRM Customer Engagement Centre.
Founded in 2003, makepositive is a multi-award-winning Salesforce consulting partner, with circa 180 employees, offices in London and Manchester, and a development centre in India. makepositive has over 120 Salesforce-accredited consultants with 700+ Salesforce certifications amongst them, as well as its own dedicated managed services capability. The company has delivered Salesforce projects for leading organisations, including Allocate, Aston Martin, Fujifilm, Gamma, McCarthy & Stone, Sohonet, Visioncall and Wolseley.
“With AI and conversational technologies now handling many routine CX enquiries, contact centre advisors handle a greater proportion of complex customer interactions. This has introduced more complexity on the advisor desktop, increasing the need for assistive Human Service solutions that offer true real-time digital support for advisors,” said Sabio Group’s CEO, Jonathan Gale. “Salesforce is a driving force in this space as traditional Contact Centre technologies merge with the Customer Engagement Centre market. Acquiring makepositive and bringing its proven design, implementation and maintenance skills across multiple Salesforce clouds into Sabio Group is an important and timely move.”
“In Sabio Group we have found a new, exciting home and, with access to Sabio’s resources, we will be able to accelerate our mission to deliver digital transformations for our customers,” added makepositive’s CEO, Mark Richards. “There’s a great connection and cultural fit between the two organisations.”
“Sabio will be key to helping makepositive extend its footprint and take advantage of the growing demand for solutions that deliver exceptional customer and employee experiences,” said Matt Cooksley, makepositive’s COO. “For the past 10 years, our focus has been on becoming a leading independent Salesforce consulting partner in the UK. We are now looking forward to expanding that journey with Sabio as we increase the reach and depth of our customer offerings.”
Commenting on Sabio Group’s acquisition of makepositive, Leon Mangan, Salesforce’s Senior Vice President Alliances & Channels for EMEA & LATAM, said: “Salesforce is investing for growth in the UK, and our partner ecosystem is an essential driving force behind this. It’s great that makepositive, a leading UK Salesforce consulting partner, is taking its business forward to the next level as part of the Sabio Group. We look forward to their continued success in the dynamic CRM Customer Engagement Centre space.”
Notes:
Salesforce, and others are among the trademarks of salesforce.com, inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005029/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom